Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$25.78

-0.44 (-1.68%)

07:55
02/13/18
02/13
07:55
02/13/18
07:55

Reata Pharmaceuticals to host conference call

Conference call to provide an update on the Bardoxolone rare CKD program will be held on February 13 at 8:30 am. Webcast Link

  • 13

    Feb

RETA Reata Pharmaceuticals
$25.78

-0.44 (-1.68%)

11/06/17
SBSH
11/06/17
NO CHANGE
Target $78
SBSH
Buy
Citi says time to believe in Reata's Alport syndrome data
Citi analyst Yigal Nochomovitz says it is time to believe Reata Pharmaceuticals' Alport syndrome data "are real" after the company presented positive 12-week data from the Phase 2 Cardinal trial testing bardoxolone. The shares sold off 4% Friday despite a "consistent and increasing benefit" in eGFR, a measure of kidney function, over time in a genetically-driven disease where decline in kidney function is the norm, Nochomovitz writes in a research note. Investors were hesitant to believe the data in July with only 8 patients reaching 12 weeks, but now all 30 have completed the trial and the results "are only better," the analyst contends. He keeps a Buy rating on Reata with a $78 price target. The stock closed Friday down $1.09 to $28.92.
09/13/17
LEER
09/13/17
INITIATION
Target $43
LEER
Outperform
Reata Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Reata Pharmaceuticals with an Outperform rating and $43 price target as he believes the company has a "strong development strategy" for its novel platform as evidenced by recent positive data in two orphan indications, and expects upcoming data in others to expand investor appreciation.
08/30/17
JEFF
08/30/17
INITIATION
Target $44
JEFF
Buy
Reata Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Reata Pharmaceuticals with a Buy rating and $44 price target. The company is positioned to "pursue several valuable orphan indication" markets with potential for broader use, Raycroft tells investors in a research note.
07/25/17
SBSH
07/25/17
NO CHANGE
Target $87
SBSH
Buy
Reata Pharmaceuticals price target raised to $87 from $39 at Citi
Citi analyst Yigal Nochomovitz more than doubled his price target for shares of Reata Pharmaceuticals to $87 from $39. The clinical-stage biopharmaceutical company closed yesterday up $4.37, or 14%, to $35.47. The company yesterday reported "unexpected and highly impressive" results from a Phase 2 trial testing Bardoxolone in Alport Syndrome, Nochomovitz tells investors in a research note. The data suggest "very meaningful disease reversal," the analyst argues. He believes the planned Phase 3, with data expected in 2019, should work with at least a 60% probability. Nochomovitz keeps a Buy rating on Reata shares.

TODAY'S FREE FLY STORIES

XPO

XPO Logistics

$93.56

-0.43 (-0.46%)

05:37
02/23/18
02/23
05:37
02/23/18
05:37
Recommendations
XPO Logistics analyst commentary  »

XPO free cash flow growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$39.85

0.34 (0.86%)

, BIVV

Bioverativ

$104.30

0.39 (0.38%)

05:35
02/23/18
02/23
05:35
02/23/18
05:35
Hot Stocks
Sanofi announces expiration of HSR waiting period for acquisition of Bioverativ »

Sanofi (SNY) announced…

SNY

Sanofi

$39.85

0.34 (0.86%)

BIVV

Bioverativ

$104.30

0.39 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

KNX

Knight-Swift

$47.83

-0.47 (-0.97%)

05:34
02/23/18
02/23
05:34
02/23/18
05:34
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGL

Sibanye Gold

$4.05

-0.38 (-8.58%)

05:26
02/23/18
02/23
05:26
02/23/18
05:26
Upgrade
Sibanye Gold rating change  »

Sibanye Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGIF

Ingenico Group

05:23
02/23/18
02/23
05:23
02/23/18
05:23
Downgrade
Ingenico Group rating change  »

Ingenico Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$30.53

-1.44 (-4.50%)

05:22
02/23/18
02/23
05:22
02/23/18
05:22
Hot Stocks
Momo acquires Tantan in cash, stock transaction »

Momo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$55.43

-0.27 (-0.48%)

05:20
02/23/18
02/23
05:20
02/23/18
05:20
Recommendations
GoDaddy analyst commentary  »

GoDaddy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Mar

SRE

Sempra Energy

$106.64

1.21 (1.15%)

05:19
02/23/18
02/23
05:19
02/23/18
05:19
Hot Stocks
Sempra Energy raises annualized dividend by 9% to $3.58 per share »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

MB

Mindbody

$35.55

2.2 (6.60%)

05:18
02/23/18
02/23
05:18
02/23/18
05:18
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

05:17
02/23/18
02/23
05:17
02/23/18
05:17
Upgrade
Financial Engines rating change  »

Financial Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$35.82

0.49 (1.39%)

05:14
02/23/18
02/23
05:14
02/23/18
05:14
Initiation
Okta initiated  »

Okta initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 07

    Mar

COTV

Cotiviti Holdings

$34.21

-0.32 (-0.93%)

05:11
02/23/18
02/23
05:11
02/23/18
05:11
Downgrade
Cotiviti Holdings rating change  »

Cotiviti downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARD

Ardagh Group

$19.01

0.8 (4.39%)

05:09
02/23/18
02/23
05:09
02/23/18
05:09
Recommendations
Ardagh Group analyst commentary  »

Ardagh should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$26.48

-0.29 (-1.08%)

05:03
02/23/18
02/23
05:03
02/23/18
05:03
Initiation
Boston Scientific initiated  »

Boston Scientific assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

SGMO

Sangamo

$25.40

3.2 (14.41%)

, GILD

Gilead

$79.40

-1.29 (-1.60%)

05:00
02/23/18
02/23
05:00
02/23/18
05:00
Recommendations
Sangamo, Gilead analyst commentary  »

Sangamo price target…

SGMO

Sangamo

$25.40

3.2 (14.41%)

GILD

Gilead

$79.40

-1.29 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$101.51

0.42 (0.42%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Eastman Chemical management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

Week of 2/23 Baker-Hughes…

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

San Francisco Federal…

UMICY

Umicore

$14.37

-0.185 (-1.27%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Umicore management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GVA

Granite Construction

$60.58

1.04 (1.75%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Granite Construction management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    May

LYG

Lloyds Banking

$3.92

-0.03 (-0.76%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Lloyds Banking management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RYTM

Rhythm Pharmaceuticals

$26.06

0.01 (0.04%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Rhythm Pharmaceuticals management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

NJDCY

Nidec

$38.51

0.605 (1.60%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Nidec management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MDXG

MiMedx

$8.88

-0.17 (-1.88%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
MiMedx to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.